CFTR and cystic fibrosis: Similar to the present study, Bernarde et al. [43] found that treatment with Ivacafator a CFTR potentiator (with low level antimicrobial activity) was not associated with significant changes in CF microbiome in a cohort of three individuals but rather subtle changes at the OTU level were observed.